Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.

Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, Urba WJ, Leidner RS.

J Immunother Cancer. 2019 Jul 3;7(1):165. doi: 10.1186/s40425-019-0645-6.

2.

Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.

Gunderson AJ, Yamazaki T, McCarty K, Phillips M, Alice A, Bambina S, Zebertavage L, Friedman D, Cottam B, Newell P, Gough MJ, Crittenden MR, Van der Veken P, Young KH.

PLoS One. 2019 Feb 6;14(2):e0211117. doi: 10.1371/journal.pone.0211117. eCollection 2019.

3.

A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity.

Zebertavage L, Bambina S, Shugart J, Alice A, Zens KD, Lauer P, Hanson B, Gough MJ, Crittenden MR, Bahjat KS.

PLoS One. 2019 Jan 2;14(1):e0209153. doi: 10.1371/journal.pone.0209153. eCollection 2019.

4.

Clinical Development of Novel Drug-Radiotherapy Combinations.

Ahmad SS, Crittenden MR, Tran PT, Kluetz PG, Blumenthal GM, Bulbeck H, Baird RD, Williams KJ, Illidge T, Hahn SM, Lawrence TS, Spears PA, Walker AJ, Sharma RA.

Clin Cancer Res. 2019 Mar 1;25(5):1455-1461. doi: 10.1158/1078-0432.CCR-18-2466. Epub 2018 Nov 29.

PMID:
30498095
5.

Role of the immunosuppressive microenvironment in immunotherapy.

Tormoen GW, Crittenden MR, Gough MJ.

Adv Radiat Oncol. 2018 Oct 23;3(4):520-526. doi: 10.1016/j.adro.2018.08.018. eCollection 2018 Oct-Dec. Review.

6.

Combination Immunotherapy Development in Melanoma.

Eggermont AMM, Crittenden M, Wargo J.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:197-207. doi: 10.1200/EDBK_201131. Review.

PMID:
30231333
7.

Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.

Baird JR, Bell RB, Troesch V, Friedman D, Bambina S, Kramer G, Blair TC, Medler T, Wu Y, Sun Z, de Gruijl TD, van de Ven R, Leidner RS, Crittenden MR, Gough MJ.

Cancer Res. 2018 Nov 1;78(21):6308-6319. doi: 10.1158/0008-5472.CAN-18-1652. Epub 2018 Sep 17.

PMID:
30224374
8.

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.

Crittenden MR, Zebertavage L, Kramer G, Bambina S, Friedman D, Troesch V, Blair T, Baird JR, Alice A, Gough MJ.

Sci Rep. 2018 May 3;8(1):7012. doi: 10.1038/s41598-018-25482-w.

9.

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2018 Feb 15;13(2):e0192988. doi: 10.1371/journal.pone.0192988. eCollection 2018.

10.

Amplifying IFN-γ Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity.

Alice AF, Kramer G, Bambina S, Baird JR, Bahjat KS, Gough MJ, Crittenden MR.

J Immunol. 2018 Jan 1;200(1):177-185. doi: 10.4049/jimmunol.1700909. Epub 2017 Nov 17.

11.

STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2017 Nov 14;12(11):e0187532. doi: 10.1371/journal.pone.0187532. eCollection 2017. Erratum in: PLoS One. 2018 Feb 15;13(2):e0192988.

12.

Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Baird JR, Monjazeb AM, Shah O, McGee H, Murphy WJ, Crittenden MR, Gough MJ.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):362-373. doi: 10.1016/j.ijrobp.2017.04.014. Epub 2017 Apr 19. Review.

13.

Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy.

Sckisel GD, Mirsoian A, Minnar CM, Crittenden M, Curti B, Chen JQ, Blazar BR, Borowsky AD, Monjazeb AM, Murphy WJ.

J Immunother Cancer. 2017 Apr 18;5:33. doi: 10.1186/s40425-017-0235-4. eCollection 2017.

14.

Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].

Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12. No abstract available.

PMID:
28202215
15.

Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.

Bryan RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2016 Oct;61:166-76. doi: 10.1016/j.oraloncology.2016.08.020. Epub 2016 Sep 7. Review. Erratum in: Oral Oncol. 2017 Mar;66:e3.

PMID:
27614589
16.

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.

Crittenden MR, Baird J, Friedman D, Savage T, Uhde L, Alice A, Cottam B, Young K, Newell P, Nguyen C, Bambina S, Kramer G, Akporiaye E, Malecka A, Jackson A, Gough MJ.

Oncotarget. 2016 Nov 29;7(48):78653-78666. doi: 10.18632/oncotarget.11823.

17.

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.

Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR.

J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016.

18.

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.

Friedman D, Baird JR, Young KH, Cottam B, Crittenden MR, Friedman S, Gough MJ, Newell P.

Hepatol Res. 2017 Jun;47(7):702-714. doi: 10.1111/hepr.12789. Epub 2016 Sep 22.

PMID:
27501850
19.

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR.

PLoS One. 2016 Jun 9;11(6):e0157164. doi: 10.1371/journal.pone.0157164. eCollection 2016.

20.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
21.

Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma.

Bell RB, Leidner R, Feng Z, Crittenden MR, Gough MJ, Fox BA.

J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S107-15. doi: 10.1016/j.joms.2015.05.026. Review. No abstract available.

PMID:
26608138
22.

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.

Baird JR, Friedman D, Cottam B, Dubensky TW Jr, Kanne DB, Bambina S, Bahjat K, Crittenden MR, Gough MJ.

Cancer Res. 2016 Jan 1;76(1):50-61. doi: 10.1158/0008-5472.CAN-14-3619. Epub 2015 Nov 13.

23.

Partial vs Single Aortic Clamping: What Is the Difference?

Crittenden MD.

JAMA Surg. 2016 Jan;151(1):63. doi: 10.1001/jamasurg.2015.3101. No abstract available.

PMID:
26398522
24.

Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy.

Gough MJ, Crittenden MR, Young KH.

Immunotherapy. 2015;7(8):847-9. doi: 10.2217/IMT.15.58. Epub 2015 Aug 13. No abstract available.

PMID:
26268988
25.

Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.

Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, Alderson KA, Sungur CM, Ames E, Mirsoian A, Reddy A, Alexander W, Soulika A, Blazar BR, Longo DL, Wiltrout RH, Murphy WJ.

Immunity. 2015 Aug 18;43(2):240-50. doi: 10.1016/j.immuni.2015.06.023. Epub 2015 Jul 28.

26.

Tumor immune remodeling by TGFβ inhibition improves the efficacy of radiation therapy.

Young KH, Gough MJ, Crittenden M.

Oncoimmunology. 2014 Sep 14;4(3):e955696. eCollection 2015 Mar.

27.

Current clinical trials testing combinations of immunotherapy and radiation.

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S.

Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003. Review.

28.

TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models.

Young KH, Newell P, Cottam B, Friedman D, Savage T, Baird JR, Akporiaye E, Gough MJ, Crittenden M.

Cancer Immunol Res. 2014 Oct;2(10):1011-22. doi: 10.1158/2326-6066.CIR-13-0207. Epub 2014 Jul 21.

29.

Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice.

Crittenden MR, Savage T, Cottam B, Baird J, Rodriguez PC, Newell P, Young K, Jackson AM, Gough MJ.

Radiat Res. 2014 Aug;182(2):182-90. doi: 10.1667/RR13493.1. Epub 2014 Jul 3.

PMID:
24992164
30.

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor.

Crittenden MR, Savage T, Cottam B, Bahjat KS, Redmond WL, Bambina S, Kasiewicz M, Newell P, Jackson AM, Gough MJ.

PLoS One. 2013 Jul 25;8(7):e69527. doi: 10.1371/journal.pone.0069527. Print 2013.

31.

The impact of the myeloid response to radiation therapy.

Gough MJ, Young K, Crittenden M.

Clin Dev Immunol. 2013;2013:281958. doi: 10.1155/2013/281958. Epub 2013 Apr 7. Review.

32.

Circulating and intratumoral macrophages in patients with hepatocellular carcinoma: correlation with therapeutic approach.

Newell P, Cottam B, Savage T, Hammill C, Wolf R, Bifulco C, Xiao HD, Crocenzi T, Hansen P, Crittenden M, Gough M.

Am J Surg. 2013 May;205(5):534-40. doi: 10.1016/j.amjsurg.2013.02.002.

PMID:
23592159
33.

Radiation and immunotherapy: Renewed allies in the war on cancer.

Seung SK, Curti B, Crittenden M, Urba W.

Oncoimmunology. 2012 Dec 1;1(9):1645-1647.

34.

Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy.

Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, Gough MJ.

PLoS One. 2012;7(6):e39295. doi: 10.1371/journal.pone.0039295. Epub 2012 Jun 28.

35.

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.

Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ.

Sci Transl Med. 2012 Jun 6;4(137):137ra74. doi: 10.1126/scitranslmed.3003649.

36.

Immune system plays an important role in the success and failure of conventional cancer therapy.

Gough MJ, Crittenden MR.

Immunotherapy. 2012 Feb;4(2):125-8. doi: 10.2217/imt.11.157. No abstract available.

37.

Costs and quality of life associated with radial artery and saphenous vein cardiac bypass surgery: results from a Veterans Affairs multisite trial.

Wagner TH, Sethi G, Holman W, Lee K, Bakaeen FG, Upadhyay A, McFalls E, Tobler HG, Kelly RF, Crittenden MD, Thai H, Goldman S.

Am J Surg. 2011 Nov;202(5):532-5. doi: 10.1016/j.amjsurg.2011.06.011. Epub 2011 Aug 26.

PMID:
21872209
38.

Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial.

Goldman S, Sethi GK, Holman W, Thai H, McFalls E, Ward HB, Kelly RF, Rhenman B, Tobler GH, Bakaeen FG, Huh J, Soltero E, Moursi M, Haime M, Crittenden M, Kasirajan V, Ratliff M, Pett S, Irimpen A, Gunnar W, Thomas D, Fremes S, Moritz T, Reda D, Harrison L, Wagner TH, Wang Y, Planting L, Miller M, Rodriguez Y, Juneman E, Morrison D, Pierce MK, Kreamer S, Shih MC, Lee K.

JAMA. 2011 Jan 12;305(2):167-74. doi: 10.1001/jama.2010.1976.

PMID:
21224458
39.

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA.

Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Review.

40.

Left ventricular thrombosis refractory to medical therapy.

Russell E, Chien V, Khalpey Z, Bonaca M, Aragam J, Haime M, Crittenden M.

J Am Coll Cardiol. 2010 Nov 2;56(19):e37. doi: 10.1016/j.jacc.2009.05.084. No abstract available.

41.

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD.

J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095.

42.

Combination approaches to immunotherapy: the radiotherapy example.

Gough MJ, Crittenden MR.

Immunotherapy. 2009 Nov;1(6):1025-37. doi: 10.2217/imt.09.64. Review.

PMID:
20635917
43.

Exploring variability in the causal link of HITS and cognitive decline.

Rudolph JL, Martin KK, Pochay VE, Crittenden MD.

Am J Surg. 2009 Aug 1;198(2):294-295. No abstract available.

44.

Microemboli are not associated with delirium after coronary artery bypass graft surgery.

Rudolph JL, Babikian VL, Treanor P, Pochay VE, Wigginton JB, Crittenden MD, Marcantonio ER.

Perfusion. 2009 Nov;24(6):409-15. doi: 10.1177/0267659109358207.

45.

Intraoperative myocardial acidosis as a risk for hospital readmission after cardiac surgery.

Kumbhani DJ, Healey NA, Thatte HS, Birjiniuk V, Crittenden MD, Treanor PR, Khuri SF.

Am J Surg. 2009 Sep;198(3):373-80. doi: 10.1016/j.amjsurg.2009.01.013.

PMID:
19716885
46.

Cerebral hemodynamics during coronary artery bypass graft surgery: the effect of carotid stenosis.

Rudolph JL, Sorond FA, Pochay VE, Haime M, Treanor P, Crittenden MD, Babikian VL.

Ultrasound Med Biol. 2009 Aug;35(8):1235-41. doi: 10.1016/j.ultrasmedbio.2009.04.008. Epub 2009 Jun 21.

47.

Saphenous vein conduits harvested by endoscopic technique exhibit structural and functional damage.

Rousou LJ, Taylor KB, Lu XG, Healey N, Crittenden MD, Khuri SF, Thatte HS.

Ann Thorac Surg. 2009 Jan;87(1):62-70. doi: 10.1016/j.athoracsur.2008.08.049.

PMID:
19101270
48.

Troponin I after cardiac surgery and its implications on myocardial protection, outcomes, and cost.

Rousou LJ, Crittenden MD, Taylor KB, Healey NA, Gibson S, Thatte HS, Haime M, Khuri SF.

Am J Surg. 2008 Nov;196(5):703-9. doi: 10.1016/j.amjsurg.2008.07.002. Epub 2008 Sep 11.

PMID:
18789416
49.

Intraoperative cerebral high-intensity transient signals and postoperative cognitive function: a systematic review.

Martin KK, Wigginton JB, Babikian VL, Pochay VE, Crittenden MD, Rudolph JL.

Am J Surg. 2009 Jan;197(1):55-63. doi: 10.1016/j.amjsurg.2007.12.060. Epub 2008 Aug 23. Review.

50.

Impact of intraoperative myocardial tissue acidosis on postoperative adverse outcomes and cost of care for patients undergoing prolonged aortic clamping during cardiopulmonary bypass.

Healey CM, Kumbhani DJ, Healey NA, Crittenden MD, Gibson SF, Khuri SF.

Am J Surg. 2009 Feb;197(2):203-10. doi: 10.1016/j.amjsurg.2008.01.023. Epub 2008 Aug 22.

PMID:
18722580

Supplemental Content

Loading ...
Support Center